Cargando…

New perspective towards therapeutic regimen against SARS-CoV-2 infection

The ongoing enormous loss of human life owing to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has led to a global crisis ranging from the collapse of health – care systems to socio-economic instability. As SARS-CoV-2 is a novel virus, very little information is available from resear...

Descripción completa

Detalles Bibliográficos
Autores principales: Srivastava, Vartika, Ahmad, Aijaz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152204/
https://www.ncbi.nlm.nih.gov/pubmed/34118735
http://dx.doi.org/10.1016/j.jiph.2021.05.009
_version_ 1783698554206814208
author Srivastava, Vartika
Ahmad, Aijaz
author_facet Srivastava, Vartika
Ahmad, Aijaz
author_sort Srivastava, Vartika
collection PubMed
description The ongoing enormous loss of human life owing to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has led to a global crisis ranging from the collapse of health – care systems to socio-economic instability. As SARS-CoV-2 is a novel virus, very little information is available from researchers and therefore, a rigorous effort is required to decode its pathogenicity. There are no licenced treatment options available for treating SARS-CoV-2 infections and the development of a new antiviral drug targeting coronavirus cannot happen soon. Consequently, drug repurposing is a promising solution for combating the present pandemic. In this review, we have thoroughly discussed all the proteins encoded by the SARS-CoV-2 genome; their importance in pathogenicity and their potential role in drug discovery. Also, the budding threat of co-infections by other pathogenic microbes has been highlighted. Furthermore, the advances made in the medicinal field for the treatment and prevention of this viral infection is explained. Altogether, this review will provide some insightful discussions about this infectious disease and will meet certain of the knowledge gaps which exist by presenting an exhaustive and extensive scientific report on the ongoing mission for COVID-19 drug discovery.
format Online
Article
Text
id pubmed-8152204
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences.
record_format MEDLINE/PubMed
spelling pubmed-81522042021-05-28 New perspective towards therapeutic regimen against SARS-CoV-2 infection Srivastava, Vartika Ahmad, Aijaz J Infect Public Health Article The ongoing enormous loss of human life owing to Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), has led to a global crisis ranging from the collapse of health – care systems to socio-economic instability. As SARS-CoV-2 is a novel virus, very little information is available from researchers and therefore, a rigorous effort is required to decode its pathogenicity. There are no licenced treatment options available for treating SARS-CoV-2 infections and the development of a new antiviral drug targeting coronavirus cannot happen soon. Consequently, drug repurposing is a promising solution for combating the present pandemic. In this review, we have thoroughly discussed all the proteins encoded by the SARS-CoV-2 genome; their importance in pathogenicity and their potential role in drug discovery. Also, the budding threat of co-infections by other pathogenic microbes has been highlighted. Furthermore, the advances made in the medicinal field for the treatment and prevention of this viral infection is explained. Altogether, this review will provide some insightful discussions about this infectious disease and will meet certain of the knowledge gaps which exist by presenting an exhaustive and extensive scientific report on the ongoing mission for COVID-19 drug discovery. Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. 2021-07 2021-05-26 /pmc/articles/PMC8152204/ /pubmed/34118735 http://dx.doi.org/10.1016/j.jiph.2021.05.009 Text en © 2021 Published by Elsevier Ltd on behalf of King Saud Bin Abdulaziz University for Health Sciences. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Srivastava, Vartika
Ahmad, Aijaz
New perspective towards therapeutic regimen against SARS-CoV-2 infection
title New perspective towards therapeutic regimen against SARS-CoV-2 infection
title_full New perspective towards therapeutic regimen against SARS-CoV-2 infection
title_fullStr New perspective towards therapeutic regimen against SARS-CoV-2 infection
title_full_unstemmed New perspective towards therapeutic regimen against SARS-CoV-2 infection
title_short New perspective towards therapeutic regimen against SARS-CoV-2 infection
title_sort new perspective towards therapeutic regimen against sars-cov-2 infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8152204/
https://www.ncbi.nlm.nih.gov/pubmed/34118735
http://dx.doi.org/10.1016/j.jiph.2021.05.009
work_keys_str_mv AT srivastavavartika newperspectivetowardstherapeuticregimenagainstsarscov2infection
AT ahmadaijaz newperspectivetowardstherapeuticregimenagainstsarscov2infection